The online version of this article (doi:10.1186/s12985-017-0705-9) contains supplementary material, which is available to authorized users.
Nullbasic is a mutant HIV-1 Tat protein that inhibits HIV-1 replication via three independent mechanisms that disrupts 1) reverse transcription of the viral RNA genome into a DNA copy, 2) HIV-1 Rev protein function required for viral mRNA transport from the nucleus to the cytoplasm and 3) HIV-1 mRNA transcription by RNA Polymerase II. The Nullbasic protein is derived from the subtype B strain HIV-1BH10 and has only been tested against other HIV-1 subtype B strains. However, subtype B strains only account for ~10% of HIV-1 infections globally and HIV-1 Tat sequences vary between subtypes especially for subtype C, which is responsible for ~50% HIV-1 infection worldwide. These differences could influence the ability of Tat to interact with RNA and cellular proteins and thus could affect the antiviral activity of Nullbasic. Therefore, Nullbasic was tested against representative HIV-1 strains from subtypes C, D and A/D recombinant to determine if it can inhibit their replication.
Nullbasic was delivered to human cells using a self-inactivating (SIN) γ-retroviral system. We evaluated Nullbasic-mCherry (NB-mCh) fusion protein activity against the HIV-1 strains in TZM-bl cell lines for inhibition of transactivation and virus replication. We also examined antiviral activity of Nullbasic-ZsGreen1 (NB-ZSG1) fusion protein against the same strains in primary CD4+ T cells. The Nullbasic expression was monitored by western blot and flow cytometry. The effects of Nullbasic on primary CD4+ T cells cytotoxicity, proliferation and apoptosis were also examined.
The results show that Nullbasic inhibits Tat-mediated transactivation and virus replication of all the HIV-1 strains tested in TZM-bl cells. Importantly, Nullbasic inhibits replication of the HIV-1 strains in primary CD4+ T cells without affecting cell proliferation, cytotoxicity or level of apoptotic cells.
A SIN-based γ-retroviral vector used to express Nullbasic fusion proteins improved protein expression particularly in primary CD4+ T cells. Nullbasic has antiviral activity against all strains from the subtypes tested although small differences in viral inhibition were observed. Further improvement of in γ-retroviral vector stable expression of Nullbasic expression may have utility in a future gene therapy approach applicable to genetically diverse HIV-1 strains.
Additional file 1: Expression of NB-ZSG1 and ZSG1 in CD4+ T cell lysates detected by Western Blot. Cell lysates prepared from non-transduced CD4+ T cell (NT), CD4-NB-ZSG1 and CD4-ZSG1 cells were assayed by SDS-PAGE and Western Blot. The blots were probed with anti-Tat, anti-ZSG1 and anti-β-tubulin antibodies as indicated, which were detected using appropriate HRP-conjugated secondary and chemiluminescence. (PDF 24 kb)12985_2017_705_MOESM1_ESM.pdf
UNAIDS. How AIDS change everything. MDG 6: 15 years, 15 lessons of hope from the AIDS response; 2015.
Campo J, Jamjian C, Goulston C. HIV Antiretroviral Drug Resistance. J AIDS Clinic Res S. 2012;5:2.
Jin H, Li D, Sivakumaran H, Lor M, Rustanti L, Cloonan N, Wani S, Harrich D. Shutdown of HIV-1 Transcription in T Cells by Nullbasic, a Mutant Tat Protein. MBio. 2016;7.
Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, Oliveira M, Detorio M, Wainberg MA. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother. 2002;46:2087–94. CrossRefPubMedPubMedCentral
Pai NP, Shivkumar S, Cajas JM. Does Genetic Diversity of HIV-1 Non-B Subtypes Differentially Impact Disease Progression in Treatment-Naive HIV-1–Infected Individuals? A Systematic Review of Evidence: 1996–2010. JAIDS J Acq Imm Def. 2012;59:382–8. CrossRef
Lihana RW, Ssemwanga D, Abimiku A, Ndembi N. Update on HIV-1 diversity in Africa: a decade in review. AIDS Rev. 2012;14:83–100. PubMed
Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol. 2000;74:8358–67. CrossRefPubMedPubMedCentral
Swift S, Lorens J, Achacoso P, Nolan GP. Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol. 2001;Chapter 10:Unit 10 17C. PubMed
- A mutant Tat protein inhibits infection of human cells by strains from diverse HIV-1 subtypes
Min Hsuan Lin
Daniel J. Rawle
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II